Jiabin Ma

Jiabin Ma

Auto-generated profile, based on publicly available information

Jiabin Ma

Department of Radiation Oncology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, China

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
2 December 2022 in iScience
Verified
Journal Article
Open access
GKGuohuang Kang
Guohuang Kang
GZgeng zhong
geng zhong
JMJiabin Ma
Jiabin Ma
RYRui Yin
Rui Yin
KCKangning Cai
Kangning Cai
YCYidan Cao
Yidan Cao
Ethylene carbonate (EC) in the electrolyte is not stable in cells operated at high voltage (≥4.4V) or with Li metal anode, which greatly reduce the energy density and lifetime of the rechargeable lithium battery. Herein, an EC-free linear alkyl carbonate-based electrolyte is developed, which enables the high-voltage (≥4.4V) and low-temperature (−30°C) application of Ni-rich cathode (LiNi0.8Mn0.1Co0.1O2, NCM811). The EC-free system, consisting of LiPF6 and LiNO3 in ternary linear alkyl carbonates, possesses low viscosity, weakly solvated structure, and high interfacial stability with both the Ni-rich cathode and the Li metal anode to avoid continuous electrode/electrolyte side reactions and metal dissolution from the cathode. As a result, the Li||NCM811 cell delivers remarkable capacity retention of 93 ± 0.5% at the voltage of 4.4V and 88 ± 0.6% at 4.5V over 100 cycles. This study provides very encouraging perspective to develop EC-free carbonate-based electrolyte for high-voltage and low-temperature application in high-energy-density rechargeable lithium batteries.

1 December 2020 in Cancer Management and Research
Verified
Journal Article
Open access
PDF file
SSShuai Sun
Shuai Sun
XLXin Lian
Xin Lian
XLXiaoliang Liu
Xiaoliang Liu
JMJiabin Ma
Jiabin Ma
XHXiaorong Hou
Xiaorong Hou
KHKe Hu
Ke Hu
Objective: To evaluate the prognostic factors and optimal management of cervical cancer patients with brain metastasis (BM). Materials and Methods: We retrospectively reviewed the medical records of 7098 consecutive patients with cervical cancer from January 2000 to December 2019. Data for a total of 24 BM patients with cervical cancer were analyzed retrospectively in the present study. Results: The incidence of BM from cervical cancer in our institution was 0.38%. The mean survival time was 7.2 months (median 6.2 months, 0.1– 21.2 months). In the univariate analysis, the histopathology of neuroendocrine cancer, 2018 FIGO stage, Karnofsky performance status (KPS) at BM diagnosis, and treatment strategy were identified to be significant prognostic indicators for the survival of patients with BM from cervical cancer. In the multivariate analysis, KPS, chemotherapy, and radiotherapy were independent prognostic factors for survival. Recursive partition analysis (RPA) appeared to be a better prognostic tool than the other prognosis scoring classification systems. Conclusion: When patients with BM from cervical cancer have good performance status and undergo comprehensive treatment, such as radiotherapy and chemotherapy, their survival time could be significantly prolonged. Patients with surgical indications may get better survival by postoperative radiotherapy and chemotherapy. Patients with BMs ≥ 3 may get better survival by whole-brain radiotherapy. But further studies are needed regarding the selection of surgical indications and radiotherapy modes. The prognosis scoring classification system for BM from cervical cancer needs to be improved.

1 September 2020 in Cancer Management and Research
Verified
Journal Article
Open access
PDF file
JMJiabin Ma
Jiabin Ma
WWWeiping Wang
Weiping Wang
JSJing Shen
Jing Shen
XHXiaorong Hou
Xiaorong Hou
XLXin Lian
Xin Lian
FZFuquan Zhang
Fuquan Zhang
Objective: To determine the toxicity and efficacy of radiotherapy for cervical cancer in patients with systemic lupus erythematosus (SLE). Methods: Medical records of patients with SLE who received radiation for cervical cancer from January 2011 to January 2019 were reviewed. For definitive radiotherapy, a dose of 50.4 Gy in 28 fractions was delivered by intensity-modulated radiation therapy (IMRT) combined with high-dose-rate brachytherapy of 28 to 30 Gy in 5 fractions. A dose of 45 to 50.4 Gy in 25– 28 fractions was delivered for postoperative radiation. All patients were in remission with or without a low dosage of prednisone or immunosuppressive medication. Survival data were analyzed with the Kaplan–Meier method. The incidence of severe toxicities among patients was compared with the chi-square test or Fisher’s exact test. Results: Twelve patients with SLE were included in this study. Definitive radiotherapy was delivered in 7 patients with FIGO (2009) stage II–III disease. Five patients with FIGO I disease received postoperative radiation. The median follow-up time was 22.1 months. The 3-year overall survival (OS) and 3-year progression-free survival (PFS) were 77.8% and 83.3%, respectively. One patient of definitive radiotherapy and one patient of postoperative radiation died due to distant metastasis of cervical cancer. Grade 3 or higher acute and chronic reactions occurred in 58.3% and 8.3% patients, respectively. Acute grade 3 or higher toxicity correlated with the presence of chemotherapy (p = 0.045). Conclusion: Modern radiotherapy for cervical cancer was well tolerated in SLE patients with remission and provided a favorable outcome.

1 July 2021 in Cancer Management and Research
Verified
Journal Article
Open access
PDF file
MJMeng Jin
Meng Jin
XLXia Liu
Xia Liu
JMJiabin Ma
Jiabin Ma
XSXiansong Sun
Xiansong Sun
HZHongnan Zhen
Hongnan Zhen
FZFuquan Zhang
Fuquan Zhang
Purpose: In the management of breast-conserving radiotherapy, computed tomography (CT) simulation is now commonly used to identify tumor bed while has difficulties defining precisely. We aimed to evaluate the impact of magnetic resonance (MR) and CT simulation on defining the postoperative tumor bed for breast-conserving radiotherapy in patients without the aid of surgical clips. Methods: From August 2018 to March 2019, twenty patients with T 1-2N 0M 0 breast cancer at our institution were enrolled. All the patients underwent breast-conserving surgery without implantation of surgical clips and were prepared to receive radiotherapy. CT and MR images were acquired on the same day for each patient. Three radiation oncologists independently assigned cavity visualization score (CVS) and delineated the tumor bed based on first the CT then the MR images. Interobserver variability was assessed by volumes, generalized conformity index (CIgen) and the distance between the centers of mass (dCOM). Differences in mean values for parameters were tested by paired t-test or one-way analysis of variance, as appropriate. Results: First, the mean volumes of tumor bed derived from MR were 22%, 27% and 21% smaller than those based on CT images for each observer. In addition, the mean CIgen was significantly superior, and dCOM was smaller for MR than for CT images (CIgen: 0.59 vs 0.52, P= 0.008; dCOM: 1.30 cm vs 1.39 cm, P= 0.095). Moreover, the mean CVS was 3.23± 1.34 and 2.43± 0.92 for MR and CT images, respectively (P= 0.035). Last, a positive association was observed between the CVS and CIgen for both modalities (P< 0.01). Conclusion: Compared to CT, MR can improve the visualization of changes in the postoperative tumor bed. In addition, MR can yield a more precise definition of the tumor bed and improve the consistency of tumor bed contouring in patients without surgical clips.

1 January 2026 in Journal of Gynecologic Oncology
Verified
Journal Article
Open access
JMJiabin Ma
Jiabin Ma
GWGuangyu Wang
Guangyu Wang
WWWeiping Wang
Weiping Wang
HYHua Yang
Hua Yang
YYYutian Yin
Yutian Yin
KHKe Hu
Ke Hu
To evaluate the efficacy and safety of extended-field intensity-modulated radiotherapy (EF-IMRT) combined with concurrent chemotherapy and high-dose-rate (HDR) brachytherapy in locally advanced cervical cancer with positive para-aortic (PALN) or common iliac lymph nodes (CILN). A multicenter prospective study was conducted involving patients diagnosed with biopsy-proven cervical cancer and positive PALN or CILN, enrolled from 11 hospitals in China. All patients were treated with EF-IMRT with concurrent chemotherapy followed by HDR brachytherapy. The primary endpoint was progression-free survival (PFS), with overall survival (OS), local progression-free survival (LPFS), distant metastasis-free survival (DMFS), and adverse events as secondary endpoints. Between October 2015 and July 2018, 204 patients with cervical cancer were evaluable in this study, with a median follow-up of 68.7 months. The 3-year and 5-year PFS were 68.3% and 64.6%, respectively. OS at 3 and 5 years were 76.4% and 69.5%, respectively. The 5-year LPFS and DMFS were 83.1% and 70.1%, respectively. Notably, patients with positive PALN had significantly lower PFS, OS, LPFS, and DMFS compared to those with negative PALN (p<0.05). Among patients with PALN involvement, those with positive CILN exhibited significantly lower PFS and DMFS compared to those with negative CILN (p<0.05). Acute grade ≥3 gastrointestinal toxicities occurred in 16.7% of patients, and chronic grade ≥3 gastrointestinal toxicities were observed in 3% of patients. This multicenter study demonstrated that EF-IMRT with concurrent chemotherapy was tolerable and effective for cervical cancer, with favorable local control and OS outcomes. Chinese Clinical Trial Registry (ChiCTR) Identifier: 17011347.

1 January 2026 in Journal of Gynecologic Oncology
Verified
Journal Article
Open access
PDF file
LXLingxia Xin
Lingxia Xin
KRKang Ren
Kang Ren
ZYZihan Yan
Zihan Yan
JMJiabin Ma
Jiabin Ma
WWWenhui Wang
Wenhui Wang
FZFuquan Zhang
Fuquan Zhang
Xin L, et al. J Gynecol Oncol. 2026 ;37:e107. https://doi.org/10.3802/jgo.2026.37.e107